MediWound

MediWound Ltd. is a global leader in developing enzymatic therapeutics for non-surgical tissue repair. Their approved product, NexoBrid®, is used for early burn eschar removal, while their pipeline includes EscharEx® for chronic wounds and MW005 for basal cell carcinoma. These innovative therapies aim to improve patient outcomes, reduce healthcare costs, and minimize the need for surgery.

Country

Israel

Website

mediwound.com

Founded

2000

Social

Source of information:

mediwound.com

Add to My List

Key Executives

Ofer Gonen

Chief Executive Officer

Lior Rosenberg

Founder

Industries

Med Tech

Add Your Company

Disclaimer

The content of this website is not directed at or intended for persons in the United Kingdom or any other jurisdiction where the provision of the website or services would breach any applicable law or registration or would require any registration or license in any such jurisdiction. The content of this website should not be regarded as an invitation or inducement to engage in investment activity, to any person in the United Kingdom and investment opportunities described on this website are not intended to be acted upon by any persons in the United Kingdom.